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1. Introduction 
Hypercholesterolemia is a major risk factor for atherosclerosis and its premature 
cardiovascular complications. Hypercholesterolemia can be multifactorial (diet, genetic 
background...) or - less frequently - monogenic, leading to Autosomal Dominant 
Hypercholesterolemia (ADH, OMIM #143890). ADH is characterised by a selective elevation 
of plasmatic Low Density Lipoprotein (LDL) levels, tendinous xanthoma and premature 
coronary heart disease. ADH has proven to be genetically heterogeneous and associated 
with defects in at least 3 different genes: LDLR (LDL receptor), APOB (apolipoprotein B) and 
PCSK9 (proprotein convertase subtilisin-kexin type 9). 
Familial hypercholesterolemia (FH, OMIM #606945) is the most frequent form of ADH and 
is due to mutations within the gene encoding the LDL specific receptor. FH is an autosomal 
co-dominant trait, with homozygotes being more severely affected than heterozygotes 
(Goldstein and Brown, 1989). FH is also one of the most common inherited disorders with a 
frequency of heterozygotes estimated to be 1:500 and a frequency of homozygotes being ≈ 
1:106 in most populations. In certain communities, such as French Canadians (Moorjani et al. 
1989), Finns (Koivisto et al. 1992), Afrikaners (Kotze et al. 1989; Leitersdorf et al. 1989), 
Druze (Landsberger et al. 1992) and Lebanese (Lehrman et al. 1987), FH frequency can be as 
high as 1/67 because of founder effects. 
2. The LDL receptor 
The human low-density lipoprotein receptor mediates the transport of LDL into cells via 
endocytosis, and thus plays a major role in the clearance of lipoproteins from the blood. In 
1973, by studying homozygous patient fibroblasts, Michael S. Brown and Joseph L. 
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Goldstein showed that the deficient protein in Familial Hypercholesterolemia was the LDL 
receptor (Goldstein and Brown, 1985).  
The LDLR gene is localised at 19p13.1-p13.3, spans 45 kb and includes 18 exons (Lindgren et 
al. 1985; Yamamoto et al. 1984). It is ubiquitously expressed and encodes a glycoprotein of 
839 amino acids that is pivotal in cholesterol homeostasis. The correspondence between the 
6 functional domains of the protein and the exons of the LDLR gene is now well-established 
(Figure 1) (See Jeon and Blacklow 2005 for a review). 
1. The signal peptide (21 amino acids) encoded by exon 1 is necessary for transport to the 
cell membrane and is cleaved during translocation into the endoplasmic reticulum (ER). 
2. The ligand binding domain, encoded by exons 2 to 6 mediates the interaction with 
lipoproteins. This domain is made of seven modules named LDL receptor type A repeat 
(LR) and homologous to sequences of the protein C9 of the complement cascade (Südolf 
et al. 1985). Each LR module is about 40 residues long, has six conserved cysteine 
residues, and contains a conserved acidic region near the C-terminus which serves as a 
calcium-binding site (Yamamoto et al. 1984, Fass et al. 1997). Mutational studies of the 
seven LR modules of the LDL receptor indicate that modules 3-7 all contribute 
significantly to the binding of LDL particles (Russel et al. 1989). Each of the LR5 and 
LR6 modules is essentially structurally independent of the other (North et al. 1999). 
3. The EGF precursor homology domain (400 amino acids encoded by exons 7 to 14) is 
made of three 40 amino acids repeats homologous to the EGF precursor, and is 
involved in the dissociation of the receptor and the lipoprotein in the endocytosis 
machinery. The two first repeats are contiguous and separated from the third by a 280 
amino acid sequence that contains five copies of a conserved motif (YWTD) repeated 
once for each of 40-60 amino acids. The first epidermal growth factor-like repeat (EGF-
A) in the EGF homology domain interacts in a sequence-specific manner with 
proprotein convertase subtilisin/kexin type 9 (PCSK9) (Zhang et al. 2007, Kwon et al. 
2008). PCSK9 post-translationally regulates hepatic LDL receptors by binding to them 
on the cell surface and by leading to their degradation. Gain-of-function mutations that 
increase the affinity of PCSK9 toward the receptor and increase plasma LDL-cholesterol 
levels in humans, have been reported in the PCSK9 gene associated with Autosomal 
Dominant Hypercholesterolemia (Abifadel et al. 2003, 2009). Loss-of-function mutations 
that decrease the affinity of PCSK9 toward the receptor have also been reported in the 
PCSK9 gene associated with low plasma levels of LDL (Cohen et al. 2005). 
4. Exon 15 encodes a 58 amino acid sequence that is enriched in serines and threonines, 
which serve as attachment sites for O-linked sugar chains. The absence of this exon has 
no significant functional consequence in cultured hamster fibroblasts (Davis et al. 1986). 
5. The 22 amino acids membrane-anchoring domain, encoded by exon 16 and the 5’ end of 
exon 17, is essential to the attachment of the receptor to the cell membrane. 
6. The 50 amino acid cytoplasmic tails, encoded by the remainder of exon 17 and the 5’ 
end of exon 18, are involved in the endocytosis of the protein. The NPXY motif was 
shown to interact with the AP-2 clathrin adaptor and thus is important in the 
localisation of the receptor in coated pits on the cell surface. The NPXY motif was also 
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shown to interact with the phosphotyrosine binding (PTB) domain of a specific clathrin 
adaptor protein encoded by the LDLRAP1 gene. Mutations in the LDLRAP1 gene have 
been reported in Autosomal Recessive Hypercholesterolemia (Garcia et al. 2001, Soutar 
2010). 
The reminder of exon 18 specifies the 2,6 kb 3’ untranslated region of the mRNA. 
 
Figure 1. Correspondence between functional domains of the protein and exons of the LDLR gene. 
In normal fibroblasts, the precursor protein is modified in the ER: the 21 amino acid signal 
peptide is cleaved and the precursor of 120 kDa is O-glycosylated to give rise to the 160 kDa 
protein. The resultant mature protein is transported from the Golgi apparatus to the cell 
surface within 30 minutes. The transmembrane receptor is present at the surface of most cell 
types and mediates the transport of LDL into cells, via receptor-mediated endocytosis, thus 
playing a pivotal role in cholesterol homeostasis (Goldstein and Brown, 2009). By endosome 
acidification, the lipoparticle is dissociated from the receptor, degraded and the receptor 
recycles back into the membrane. 
3. Mutations in the LDLR gene 
Mutations involving a small number of nucleotides, from point mutations to small deletions 
or insertions, account for 90% of all mutations in the LDLR gene, while the remaining are 
major rearrangements due to unequal recombination between the 30 Alu sequences 
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identified throughout the gene (Hobbs et al. 1990). To date, more than 1400 point mutations 
and small deletions or insertions associated with FH have been reported in the LDLR gene 
(http://www.ucl.ac.uk/fh and www.umd.be/LDLR/).  
The UMD-LDLR database (www.umd.be/LDLR/) actually includes 1404 point mutations, 
small deletions or insertions and mutations affecting splicing (intronic mutations) in the 
LDLR gene reported in the literature. It cannot accommodate mutations from the UTR and 
promoter regions, and large deletions or insertions or indels. In addition, two mutations that 
affect the same allele are entered as two different records linked by the same sample ID. If 
the same mutation has been reported in apparently unrelated patients (for example, the 
c.1A>C (p.Met1Leu) identified in Spanish (Chaves et al. 2001), British (Day et al. 1997) and 
Dutch patients (Fouchier et al. 2005), separate entries were made for each patient as 
recurrent mutations, in the absence of haplotypes demonstrating a common ancestor. 
Among these 1404 small DNA variations of the LDLR gene, 58.5% are missense mutations, 
21.7% are small deletions or insertions, 10.4 % are nonsense and 9.4% are splice site 
mutations. A large majority of these small DNA variations are single nucleotide 
substitutions (76.6%, 1076/1404), including 75.1% missense, 13.6% nonsense and 11.3% splice 
site mutations. 
3.1. Missense mutations 
Missense mutations are the most numerous of the small DNA variations (58.5%, 821/1404) 
reported in the LDLR gene in association with Familial Hypercholesterolemia (FH). Like the 
other small DNA variations in the LDLR gene, missense mutations are widely distributed 
throughout the whole sequence of the gene (Figure 2). Therefore, no real mutation hot spot 
can be defined which sustains the need to scan the whole gene sequence to identify FH-
causing mutations in the diagnostic procedures. 
The CpG dinucleotide has been shown to be a hot spot for mutations in humans because it 
can undergo oxidative deamination of 5-methyl cytosine (Krawczak et al. 1998). The LDLR 
gene sequence includes 123 CpG dinucleotides, accounting for 4.8% of the coding sequence. 
This ratio is similar to the mean percentage of CpG (3.7%) in the coding sequence of a large 
number of genes involved in human diseases and localised on autosomes (Cooper and 
Krawczak 1990). Missense mutations are the only substitutions in the LDLR gene occurring 
at the CpG dinucleotide for 4.8% (46/954) of all the single nucleotide variations. 
Interestingly, in the LDLR gene, the percentage of substitution occurring at the CpG (4.8%) 
is significantly lower than the mean observed for disease-causing mutations in other genes 
(37%) (Cooper and Krawczak 1990). There is no explanation, to date, for this observation. 
In the LDL receptor protein, the most numerous amino acids are aspartate (8.7%), serine 
(8.1%), leucine (7.7%), cysteine (7.3%), glycine (7.2%) and valine (6.7%). The less represented 
amino acids are methionine (1.3%), tyrosine (2.0%), histidine (2.2%), tryptophane (2.3%) and 
phenylalanine (3.0%). This distribution of amino acids is consistent with the one reported for 
human proteins in general, with an exception for cysteine that is less abundant (3%) (Lewin 
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1990). The LDL receptor is known to be a cysteine-rich protein in which disulphide bonds 
between two cysteines are essential for ensuring the correct folding of 10 major modules 
necessary for protein activity (Russell et al. 1989, Kurniawan et al. 2001). 
The number of mutations affecting an amino acid is not always related to its frequency in 
the protein. Cysteine, tryptophane and aspartate are more frequently affected than others 
residues, indicating that they are essential actors of protein activity. Substitutions affect 57 
(90%) of the 63 cysteines of the LDL receptor, 43 (57%) of the 75 aspartates and 12 (60%) of 
the 20 tryptophanes. Cysteines are involved in the folding of the ligand binding and EGF-
like domains. Aspartates are also highly conserved residues of the repeated modules of the 
LDL binding domain. Their negative charges are involved in bonds with positively charged 
residues of the apo B and apo E ligands. Apart from its hydrophobicity, tryptophane does 
not have a structural or functional role as manifest as those of a cysteine or a charged 
residue. However, along with methionine, tryptophane is the only amino acid encoded by a 
single codon, probably explaining its “more mutable” trait observed here. 
 
Figure 2. Distribution of point mutations within the LDL receptor gene (LDLR). 
A certain proportion of the disease-causing substitutions (missense and nonsense 
mutations), ~25%, have been shown to alter functional splicing signals within exons, such as 
exonic splicing enhancers (ESE), to create an alternative splice site within exons that is used 
preferentially, or induce the loss of the consensus exonic splice site (Cartegni et al. 2002, 
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Sterne-Weiler et al. 2011). Within the LDLR gene, 28.4% of the reported missense mutations 
are predicted to alter functional splicing signals. The missense mutation c.2140G>C 
(p.Glu714Gln) that was predicted to be benign with four prediction tools for substitutions 
(Polyphen*, SIFT*, Pmut* and SNPs3D*) was predicted to create the loss of the intron 14 
donor splice site with either NetGene2* and NNSPLICE* prediction tools for splice site 
mutations (Marduel et al. 2010). It is clear, however, that mRNA analyses are necessary to 
support these predictions, as performed for a small number of exonic substitutions. The 
conservative amino acid substitution c.2389 G>T (p.V776L) that would be unlikely to affect 
LDL receptor function, concerns the last nucleotide of exon 16 and causes exon 16 skipping 
(Bourbon et al. 2009). These missense mutations would therefore be likely to exert their 
major pathological effects on splicing rather than through an alteration in the amino acid 
sequence of the LDL receptor. This is reinforced by the observation of several silent 
substitutions associated with the clinical phenotype of familial hypercholesterolemia. The 
silent mutation p.Leu605Leu (c.1813C>T) was predicted to create a new donor splice site 
AGGT at position 1813 in exon 12. The use of this new donor site would lead to the 
substitution of leucine 605 by a threonine, the deletion of 11 amino acids (from Alanine 606 
to Aspartate 616), a frameshift and the appearance of a premature termination 49 codons 
further on (Marduel et al. 2010). The variant, c.621C>T (p.Gly207Gly), was found to be 
associated with altered splicing. The nucleotide change leading to p.Gly207Gly resulted in 
the generation of new 3'-splice donor site in exon 4 of the LDL receptor gene. Splicing of this 
alternate splice site leads to an in-frame 75-base pair deletion in a stable mRNA of exon 4 
and nonsense-mediated mRNA decay (Defesche et al. 2008). The silent mutation, 
p.Arg406Arg, that also introduces a new splice site, causes a deletion of 31 bp in the LDLR 
mRNA sequence, and introduces a premature termination 4 codons further on (Bourbon et 
al. 2007).  
 
NetGene2 http://www.cbs.dtu.dk/services/NetGene2/ 
NNSPLICE http://www.fruitfly.org/seq_tools/splice.html 
Polyphen http://genetics.bwh.harvard.edu/pph/ 
SIFT  http://sift.jcvi.org/ 
Pmut  http://mmb2.pcb.ub.es:8080/PMut/ 
SNP3D  http://www.snps3d.org/ 
Tools for in silico prediction of protein function. 
3.2. Frameshift mutations 
Among the 1404 small DNA variations of the LDLR gene, a total of 305 (21.7%) are small 
deletions or insertions, including 261 (85.6%) independent mutations leading to a frameshift 
and 55 (14.4%) in-frame deletions or insertions. This proportion of in-frame small deletions 
or insertions is consistent with observations made for other disease-causing genes (Cooper, 
Antonarakis and Krawczak 1995). The frameshift mutations are due to either a small 
deletion (176/261, 12.5%) or insertion/duplication (85/261, 6.0%) of a few nucleotides (from 1 
to 49 for deletions, from 1 to 23 for insertions). The sequence context analysis provides 
 
Missense Mutation in the LDLR Gene: A Wide Spectrum in the Severity of Familial Hypercholesterolemia 61 
evidence that a repeated motif flanking the frameshift event could be involved in the 
aetiology of the mutation in 48.0% of the deletional events and in 29.2% of the insertional 
events. 
Half of the frameshift mutations involved a single nucleotide: 58.5% (103/176) among 
deletions and 56.5% (48/85) among insertions. In half of the deletion cases and in half the 
insertion cases, the single nucleotide deletion/insertion occurs within runs of 2 to 7 identical 
bases. Runs of identical bases are known to cause deletions/insertions according to the 
slipped mispairing mechanism occurring at DNA replication (Ball et al. 2005).  
Deletions involving larger sequences (from 2 to 49 bp) can be divided into three different 
types: (1) One of the repeated flanking sequences is included in the deletion, which is also 
explained by the slipped mispairing mechanism occurring at DNA replication (Ball et al. 
2005); (2) The repeated sequences flanking the deletion are not included in the frameshift 
mutation, which is explained by homologous recombination between palindromic or 
symmetric repeated sequences (Cooper 1995); (3) Parts of the flanking repeated sequences 
are included in the deletion. To date, no molecular mechanism has been identified to explain 
such deletional events. 
Insertions involving larger sequences (from 2 to 23 bp) can be explained by the same 
mechanisms as described for deletions, and can be divided into two different types: (1) The 
inserted sequence is a duplication; (2) The inserted sequence is new within the LDLR gene 
sequence. This latter observation raises the hypothesis that very probably insertions do not 
occur at random but rather in order to create repeated sequences that were not present in the 
original gene sequence. A consensus sequence, GTAAGT, was frequently identified flanking 
small deletions or insertions (Ball et al. 2005). In the LDLR gene sequence, this consensus is 
present at the 3’ end of exon 4 at position c.681-687. Among the 96 deletions (in frame and 
frameshift) in the LDLR gene, 11 (11.5%) are at this position pointing to a discrete hot spot for 
insertions, as observed in Figure 2 and in accordance with previous reports (Kotze et al. 1996). 
3.3. Nonsense mutations 
Nonsense mutations represent 10.4% (146/1404) of the small DNA variations in the LDLR 
gene, and 13.6% (146/1076) of the FH-causing substitutions. 
Among the 860 codons of the LDLR gene sequence, 253 potential stop codons (codons that 
can be turned into a stop codon with only one substitution) were identified (29.4%) and 
were not equally distributed throughout the whole gene. In exons 2 to 8, more than 33% of 
the protein codons are potential stop codons, while less than 21% of the protein codons are 
potential stop codons in exons 9, 10, 13, 15 and 16. Among these 253 potential stop codons, 
93 of them (36.8%) are affected by a mutational event. 
The number of mutations affecting potential stop codons is not always related to their 
frequency in each exon. Potential stop codons are more frequently affected by mutation in 
exons 3, 9, 10 and 14, with 57.1%, 50.0%, 46.2% and 53.3% respectively of potential stop 
codons in each exon carrying a mutational event. Conversely, in exons 1, 12, 13 and 17, 
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16.7%, 18.2%, 20.0% and 26.7% respectively of the potential stop codons are affected by a 
mutational event. 
3.4. Splice site mutations 
Among the 1404 small DNA variations of the LDLR gene, a total of 132 (9.4%) are splice site 
mutations and, among the 1076 single nucleotide FH-causing substitutions, 122 (11.4%) are 
intronic. From the analysis of a large number of genes, a mean proportion of 15% for splice site 
mutations among disease-causing DNA substitutions was evaluated (Krawczak et al. 2007). 
The expected frequency of splice site substitutions within the LDLR gene is 9% (Cooper and 
Krawczak 1990). The number of FH-causing splice site substitutions observed in this wide 
review of the literature (9.5%) is thus consistent with the expected value for the LDLR gene. 
Among the 132 splice site mutations of the LDLR gene, 14 (10.6%) are mid-intronic mutations 
situated at more than 10 bp of intron/exon junctions. Half of the intronic mutational events in 
the LDLR gene (55.3%, 73/132) affect the two canonical ‘‘AG’’ and ‘‘GT’’ highly conserved 
dinucleotides of the acceptor and donor splice sites respectively. Accordingly to the analysis of 
a large number of disease-causing mutations in different genes (Krawckak et al. 1992), within 
the LDLR gene intronic mutations affecting a donor splice site are more frequent (65.1%, 
86/132) than mutations affecting an acceptor splice site (36.4%, 48/132). 
4. Comparative analysis of mutations in the LDLR gene 
To facilitate the mutational analysis of the LDLR gene and promote the analysis of the 
relationship between genotype and phenotype, in 1997 we created a software package along 
with a computerised database: UMD-LDLR. For each mutation, information is provided at 
several levels: at the gene level (exon and codon number, wild type and mutant codon, 
mutational event, mutation name), at the mRNA level (size, processing), at the protein level 
(wild type and mutant amino acid, affected domain, activity, mutation class), and at the 
personal level (ethnic background, age, sex, body mass index and familial history of 
coronary heart disease). The software package contains routines for the analysis of the LDLR 
database that were developed with the 4th dimensionR (4D) package from ACI. The use of 
the 4D SGDB gives access to optimised multi-criteria research and sorting tools to select 
records from any field. Moreover, 13 routines were specifically developed (Varret et al. 1997, 
1998, Villèger et al. 2002, Béroud et al. 2005, www.umd.be/LDLR/). 
The aim of this study was to analyse these four mutation groups at the molecular, biological 
and clinical level. 
4.1. Analysis of LDLR mutations at the molecular level 
4.1.1. Frequency of mutational events 
DNA substitutions are of two types: transitions are interchanges of two-ring purines (A>G 
and G>A) or of one-ring pyrimidines (C>T and T>C) and, therefore, involve bases of similar 
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shape; transversions are interchanges of purine for pyrimidine bases, which involve 
exchange of one-ring and two-ring structures. Therefore, there are twice as many possible 
transversions as there are transitions. However, among human diseases-causing 
substitutions, transitions (63%) are observed more frequently than transversions (37%) 
(Cooper and Krawczak 1990). 
Accordingly, in the LDLR gene, missense mutations due to transitions (55.9%, 459/821) are 
more frequent than substitutions due to transversions (42.5%, 349/821) (Figure 3). Like 
exonic mutational events, small DNA variations at the splice site are substitutions (92.4%, 
122/132) or small deletions/insertions (9.1%, 12/132). Again, among the intronic 
substitutions, transitions (59.8%, 73/122) are observed more frequently than transversions 
(40.1%, 49/122) (Figure 3). Interestingly, in the LDLR gene, the ratio of 
transversion/transition is different for nonsense mutations. The transversions are the more 
frequent mutational event leading to a stop codon (52.7%, 77/146) compared to transitions 
(47.3%, 69/146) (Figure 3).  
 
Figure 3. Molecular events frequency of the different groups of mutations. Values are given in % of 
each event within each group of mutation. 
Because of the constraints mediated by the genetic code, transition A>G and transversion 
A>C, G>C cannot be at the origin of a stop codon. Thus, only two transitional events (G>A 
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and C>T) and 6 transversional events (A>T, C>A, C>G, G>T, T>A and T>G) lead to a stop 
codon, which means that half of the transitional events and a quarter of the transversional 
events are not involved in nonsense mutations. These constraints can explain the observed 
difference in the ratio of transversion/transition between missense and nonsense mutations. 
However, the ratio of transversion/transition is consistent with the one observed for human 
diseases-causing substitutions (Cooper and Krawczak 1990) when the three groups of 
mutations are taken together (missense, nonsense and splice). Altogether, transitions (55.9%, 
601/1076) are observed more frequently than transversions (44.1%, 475/1076). 
4.1.2. Distribution of the substitutions in the 18 exons of the LDLR gene 
The expected number of mutations in each exon is estimated by the ‘Stat exons’ tool of the 
UMD software according to the size and the composition (mutability of each codon) of each 
exon (Béroud et al. 2000 and 2005). This analysis enables the detection of a statistically 
significant difference between observed and expected mutations. 
For exons 1, 5, 8 and 10 to 14, all types of substitutions are distributed as expected. There is a 
significant excess of all substitutions (missense and nonsense) within exons 3 and 4 (Table 
1), indicating discrete mutational hot-spots and underlining the essential role played by the 
encoded domains in protein function. Exon 3 encodes the second LR motif of the ligand 
binding domain in the LDL receptor. To date, there is no data revealing a more essential 
function of this LR motif when compared to the six others. Exon 4 encodes the three central 
LR motifs (LR3, LR4 and LR5) of the ligand binding domain in the LDL receptor. The LR5 
motif have been shown to be the only one of the seven LR motifs to be able to bind the two 
ligands of the receptor, apo B and apo E, while the 6 other motifs only bind apo B (Russel et 
al. 1989). Thus, the mutations affecting this motif are associated with a more severe 
alteration of lipoprotein catabolism and, therefore, have a higher tendency to be selected by 
FH definition criteria. There is a significant deficit of all substitutions (missense and 
nonsense) within exons 15 and 16 (Table 1) indicating discrete mutational cold-spots. Exon 
15 encodes the O-linked sugar domain of the LDL receptor that has been shown to have no 
significant functional activity (Davis et al. 1986). To date, there is no explanation as to the 
observed deficit of substitutions within exon 16 which encodes the membrane-anchoring 
domain that is essential to the attachment of the receptor to the cell membrane. 
The two types of exonic substitutions (missense and nonsense) are differently distributed in 
exons 2, 6, 7, 9, 17 and 18 of the LDLR gene (Table 1). Missense mutations are the only ones 
presenting a significant excess in exons 6 and 9 and a significant deficit in exons 17 and 18 
(Table 1), maybe reflecting a bias in this analysis due to the different number of mutations of 
each type. Nonsense mutations are less numerous than missense mutations, a significant 
difference is thus less probably obtained for nonsenses than for missenses. Nevertheless, 
these observations indicate discrete mutational hot-spots within exons 6 and 9 and discrete 
mutational cold-spots within exons 17 and 18. Exon 6 encodes the last LR motif of the ligand 
binding domain in the LDL receptor. To date, there is no data revealing a more essential 
function of this LR motif when compared with the six others. Exon 9 encodes the NH2-
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terminal part of the EGF-like domain which is rich in YWTD repeats which are essential for 
the correct folding of the receptor at the cell surface. To date, there is no explanation as to 
the observed deficit of substitutions within exons 17 and 18 encoding the COOH-terminal 
part of the membrane-anchoring domain and the cytoplasmic tail, which are essential for the 
attachment of the receptor to the cell membrane and in the endocytosis of the protein. 
In exon 2, we observed a significant deficit of missenses and a significant excess of 
nonsenses (Table 1). Exon 2 encodes the first LR motif of the ligand binding domain in the 
LDL receptor. To date, there is no data revealing a more or less essential function of this LR 
motif when compared with the six others. 
Interestingly, nonsense mutations are the only ones that present a significant excess in exon 
7 of the LDLR gene (Table 1). This excess relies upon the high frequency of the c.1048C>T, 
p.Arg350X mutation, formerly called FH-Fossum. Indeed, this mutation is reported in 9 
apparently unrelated patients from different geographic origins: Norway (Solberg et al. 
1994), the Netherlands (Lombardi et al. 1995), the U.K. (Day et al. 1997), Poland (Gorski et al. 
1998), Germany (Thiart et al. 1998), Canada (Gaudet et al. 1999), Japan (Yu et al. 2002), 
Denmark (Damgaard et al. 2005) and Spain (Brusgaard et al. 2006). In the absence of 
haplotypes demonstrating a common ancestor, these mutational events are supposed to be 
recurrent and to correspond to a mutational hot-spot in the LDLR gene.  
Exon Expected 
mutations 
(%) 
Observed 
missenses 
Observed 
nonsenses 
Observed exonic 
substitutions 
% significance % significance % significance 
1 2,6 1,7 ns 2,7 ns 1,9 ns 
2 5,0 2,5 < 0.01 11,6 < 0.001 3,9 ns 
3 4,8 6,4 < 0.05 6,8 < 0.05 6,5 < 0.02 
4 14,9 20,5 < 0.001 20,5 < 0.001 20,5 < 0.001 
5 4,8 4,4 ns 3,4 ns 4,3 ns 
6 4,9 7,0 < 0.01 5,5 ns 6,8 < 0.01 
7 4,7 5,2 ns 8,9 < 0.02 5,7 ns 
8 5,0 5,3 ns 4,8 ns 5,2 ns 
9 6,6 11,2 < 0.001 4,1 ns 10,1 < 0.001 
10 8,7 7,3 ns 6,2 ns 7,1 ns 
11 4,7 4,9 ns 4,8 ns 4,9 ns 
12 5,2 6,4 ns 2,1 ns 5,7 ns 
13 5,6 5,3 ns 2,1 ns 4,8 ns 
14 5,9 6,4 ns 9,6 ns 6,9 ns 
15 6,4 1,6 < 0.001 2,1 < 0.05 1,7 < 0.001 
16 2,8 1,5 < 0.05 0,0 < 0.05 1,3 < 0.01 
17 6,1 2,3 < 0.001 4,8 ns 2,7 < 0.001 
18 1,3 0,1 < 0.01 0,0 ns 0,1 < 0.001 
Table 1. Distribution of the different exonic substitutions throughout the 18 exons of the LDLR gene. 
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4.2. Analysis of LDLR mutations at the biological level 
4.2.1. Functional classes of LDLR gene’s mutations 
Mutations in the LDLR gene have been classified into 5 functional groups based on the 
characteristics of the mutant protein produced and analysed in patients’ fibroblasts (Hobbs 
et al 1992): 
Class 1 mutations disrupt the synthesis of the LDL receptor and no precursor is produced 
(null alleles). 
Class 2 mutations block transport to the Golgi apparatus: mutations are reported in class 2A 
when a complete defect in transport to the cell membrane is observed and in class 2B when 
receptors are transported at a detectable - but markedly reduced - rate. 
Class 3 mutations produce proteins that reach the membrane but fail to bind the LDL. 
Class 4 mutations produce a receptor that binds the lipoprotein but which cannot be 
internalised. The mutations affecting the cytoplasmic domain alone are classed 4A, while 
those also affecting the membrane-spanning region are classed 4B. 
Class 5 mutations block the acid-dependant dissociation of the receptor and the ligand in the 
endosome, an essential event for receptor recycling. 
The link between the functional class type of the mutation and the severity of the disease 
has been established, and patients carrying a class 1 mutation are more severely affected 
than those with a mutation from another functional group (Hobbs et al 1992). In the UMD-
LDLR database, among the 288 single nucleotide mutations with available data concerning 
the functional group, 42.0% (121/288) are class 2B, 31.9% (92/288) are class 1, 13.5% (39/288) 
are class 5, 7.6% (22/288) are class 2A, 3.8% (11/288) are class 4A and 1.0% (3/288) are class 3. 
Class 1 mutations are mainly nonsense and frameshift mutations (66.3% nonsenses, 30.4% 
frameshifts and 3.3% missenses) and 62% of them are localised in exons 2 to 6, encoding the 
ligand binding domain for one half and in exons 7 to 14 encoding the EGF-like domain for 
the other half (Figure 4). Class 2B mutations are mainly missense mutations (92.6% 
missenses and 7.4% frameshifts) and 71% of them are localised in exons 2 to 6, encoding the 
ligand binding domain (Figure 4). Class 5 mutations are mainly missense mutations (95% 
missenses and 5% splice site mutations) and 95% of them are localised in exons 7 to 14, 
encoding the EGF-like domain (Figure 4). Class 2A, 3 and 4A mutations are mainly missense 
mutations (59% missenses, 22% nonsenses and 19% frameshifts) and 67% of them are 
localised in exons 7 to 14, encoding the EGF-like domain. As expected, the localisation of 
these different classes of mutations is consistent with the functional definition of each class. 
The higher prevalence of mutations at the origin of truncated proteins (nonsenses and 
frameshifts) within the class 1 functional group is consistent with the expected null allele 
effect of these kinds of mutations. Altogether, these observations are globally in agreement 
with the admitted dogma according to which mutations leading to a protein of abnormal 
size (nonsense, frameshift and splice) are at the origin of a more severe phenotype than 
missense mutations. 
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Figure 4. Distribution of the different mutations according to the three main functional classes. 
4.2.2. LDL receptor activity 
In the UMD-LDLR database, the LDL receptor activity measured in patients’ fibroblasts is 
available for 91 single nucleotide mutations: assays were performed for 24 heterozygote 
carriers, 22 homozygote carriers and 45 compound heterozygotes.. For homozygote carriers 
of a missense mutation, the mean LDL receptor activity is 8.7% rather than 2.7% for carriers 
of a mutation leading to a protein of abnormal size (nonsense, frameshift and splice) (Figure 
5). For heterozygote carriers of a missense mutation, the mean LDL receptor activity is 33.2% 
rather than 19.8% for carriers of an abnormal-protein mutation. Moreover, a gradient can be 
drawn for compound heterozygotes with a mean LDL receptor activity of 13.3%, 7.3% and 
3.6% for carriers of two missense mutations, one missense and one abnormal-protein 
mutation and two abnormal-protein mutations respectively (Figure 5). Once again, these 
observations are globally in agreement with an admittedly more severe phenotype for 
mutations leading to a protein of abnormal size when compared with missense mutations. 
However, missense mutations in the LDLR gene are associated with a larger spectrum of 
LDL receptor activity in fibroblasts (from 2% to 67% for heterozygotes and from 2% to 22.5% 
for homozygotes) when compared with mutations leading to a protein of abnormal size 
(from 2% to 47% for heterozygotes and from 2% to 11% for homozygotes). 
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Figure 5. LDL receptor activity in fibroblast from mutation carriers. The values are expressed as % of 
LDL binding compared with the values obtained for normocholesterolemic subjects. M: missense. N: 
null allele (frameshift, splice, nonsense). 
4.3. Analysis of LDLR mutations at the biochemical/clinical level 
4.3.1. Plasmatic lipid levels among LDLR gene mutations carriers 
Among the 1061 unique events included in the UMD-LDLR database, lipid values are 
available for only 307 of them (29%), corresponding with 25 homozygote carriers and 282 
heterozygote carriers of different molecular events within the LDLR gene (Table 2). 
According to the biochemical definition of familial hypercholesterolemia, triglycerides and 
HDL-cholesterol levels were within the normal range while the total- and LDL-cholesterol 
levels were elevated. As expected for a co-dominant disease, the total- and LDL-cholesterol 
levels were higher for homozygote mutation carriers than for molecular heterozygotes. No 
differences were observed between the four groups of mutations (missenses, frameshifts, 
splice sites and nonsenses), suggesting a similar effect of missense and mutations leading to 
a protein of abnormal size (nonsense, frameshift and splice) on the biochemical expression 
of the disease. Furthermore, no differences were observed among the distribution of total- 
and LDL-cholesterol levels among the four groups of mutations (Figure 6).  
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Figure 6. Distribution of total- and LDL-cholesterol plasmatic levels for heterozygotes carriers of a 
missense (M), a frameshift (F), a splice site (S) or a nonsense (N) mutation in the LDLR gene. 
 
HDL-Cholesterol LDL-Cholesterol Total Cholesterol Triglycerides 
Heterozygotes 
Missense N 133 144 152 137 
Mean (SD) 1.31 (0.51) 7.50 (2.38) 9.50 (2.18) 1.66 (0.94) 
Frameshift N 60 63 73 64 
Mean (SD) 1.21 (0.34) 7.84 (2.05) 9.89 (2.22) 1.39 (0.89) 
Splice N 22 25 30 24 
Mean (SD) 1.28 (0.41) 7.17 (2.08) 9.56 (2.20) 1.49 (0.54) 
Nonsenses N 24 24 27 27 
Mean (SD) 1.17 (0.40) 7.74 (1.64) 9.43 (1.53) 1.46 (0.73) 
Homozygotes 
Missense N 13 15 14 12 
Mean (SD) 1.04 (0.41) 15.55 (4.96) 17.39 (4.49) 1.42 (0.72) 
Frameshift N 3 3 3 2 
Mean (SD) 0.66 (0.21) 16.01 (1.17) 17.43 (0.93) 1.23 (0.04) 
Splice N 3 3 5 4 
Mean (SD) 0.67 (0.16) 15.25 (1.79) 18.06 (4.74) 1.34 (0.17) 
Nonsenses N 2 2 2 2 
Mean (SD) 0.87 (0.52) 17.54 (0.37) 19.56 (0.76) 2.00 (1.27) 
Table 2. Mean plasmatic lipid levels for heterozygotes and homozygote carriers of missense, 
frameshift, splice site or nonsense mutations in the LDLR gene. Values are in mmol/L. 
4.3.2. Clinical expression of familial hypercholesterolemia among LDLR gene mutation 
carriers 
Of the 1061 unique events reported in the UMD-LDLR database, clinical data is available for 
only 230 of them (22%) including 25 homozygote carriers and 215 heterozygote carriers of 
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different molecular events within the LDLR gene (Table 3). This clinical data concerns 
tendinous cholesterol deposits - such as xanthomas - and the diagnosis of premature 
coronary artery disease (CAD). Tendinous xanthomas are more frequently observed for the 
carriers of a mutation leading to a protein of abnormal size rather than for the heterozygotes 
for a missense mutation (Table 3). Once more, this observation is in agreement with the 
admitted dogma according to which mutations leading to a protein of abnormal size 
(nonsense, frameshift and splice) are at the origin of a more severe phenotype than are 
missense mutations. However, no differences were observed for the occurrence of CAD 
between missenses and those mutations leading to a protein of abnormal size (Table 3). This 
latter observation suggests a similar effect with regard to missense and mutation leading to 
a protein of abnormal size (nonsense, frameshift and splice) in the clinical expression of the 
disease. 
 
 Missenses Frameshifts, Splice sites, Nonsenses 
Sex ratio (M/F) 1.06 (83/78) 1.09 (60/55) 
Age (mean years ± SD) 39.6 ± 17.5 36.8 ± 14.9 
 N Yes (%) No (%) N Yes (%) No (%) 
CAD 100 58 42 99 52 48 
Tendinous xanthomas 106 50 50 109 65 35 
Table 3. Clinical expression of familial hypercholesterolemia for heterozygotes carriers of different 
mutations in the LDLR gene.  
5. Conclusion 
To date, it seems logical that mutations leading to a protein of abnormal size (nonsense, 
frameshift and splice) are at the origin of a more severe phenotype than missense mutations. 
The genotype/phenotype correlations performed with the UMD-LDLR database provide 
molecular, biological and clinical evidence that underlies this dogma. Moreover, missense 
mutations in the LDLR gene are the source of a wider spectrum in the severity of FH, than 
are mutations leading to a protein of abnormal size, from an almost normal phenotype to 
very severe forms of the disease. 
Mutations in the LDLR gene are numerous and frequently recurrent but, conversely, rarely 
sporadic. These observations reveal not only the high mutability at one time of this gene, but 
also that these mutations were probably selected through time. It can be postulated that a 
hypercholesterolemic mutation could have given a selective advantage to carriers and may 
be a member of the pool of alleles that constitute the «”thrifty genotype” (Neel at al. 1998). 
The thrifty genotype hypothesis suggested that, in the early years of life, the 
hypercholesterolemic genotype was thrifty in the sense of being exceptionally efficient in the 
utilisation of food. It would thereby confer a survival advantage during times of food 
shortage. However, in contemporary societies, as food is usually available in unlimited 
amounts, the thrifty genotype no longer provides a survival advantage but instead renders 
its owners more susceptible to hypercholesterolemia. 
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